6-硝基烟酸 | 33225-73-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-硝基烟酸
• 中文别名: 2-硝基吡啶-5-甲酸；2-硝基-5-吡啶羧酸
• 英文名称: 6-nitronicotinic acid
• 英文别名: 2-Nitro-5-pyridincarbonsaeure；6-nitropyridine-3-carboxylic acid
• CAS: 33225-73-9
• 化学式: C₆H₄N₂O₄
• mdl: MFCD04114183
• 分子量: 168.109
• InChiKey: JHKLCZNDTUKHHI-UHFFFAOYSA-N

物化性质

• 熔点：
  179-180 °C
• 沸点：
  434.9±30.0 °C(Predicted)
• 密度：
  1.570±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Nitronicotinic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Nitronicotinic acid
CAS number: 33225-73-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4N2O4
Molecular weight: 168.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-硝基烟酸 在 硼烷四氢呋喃络合物 、 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 35.0h， 生成 5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺
  参考文献：
  名称：

  一种新型 CDK4/6 抑制剂联合放疗在弥漫性中线胶质瘤中显示出强大的抗肿瘤功效

  摘要：

  客观的 弥漫性中线胶质瘤，H3 K27 改变 (DMG) 是一种致命的小儿脑干肿瘤。尽管为提高生存效益做出了许多努力，但其预后仍然很差。本研究旨在设计和合成一种新型 CDK4/6 抑制剂 YF-PRJ8-1011，与 palbociclib 相比，它在体外和体内对一组患者来源的 DMG 肿瘤细胞表现出更有效的抗肿瘤活性。 方法 患者来源的 DMG 细胞用于评估 YF-PRJ8-1011 的体外抗肿瘤功效。采用液相色谱串联质谱法测定YF-PRJ8-1011通过血脑屏障的活性。建立DMG患者来源的异种移植模型来检测YF-PRJ8-1011的抗肿瘤功效。 结果 结果表明，YF-PRJ8-1011在体外和体内均可抑制DMG细胞的生长。YF-PRJ8-1011 可以很好地穿透血脑屏障。与载体或 palbociclib 相比，它还显着抑制了 DMG 肿瘤的生长并延长了小鼠的总生存期。最值得注意的是，与

  DOI：

  10.1007/s11060-023-04323-5
• 作为产物：
  描述：

  6-氨基烟酸 在 硫酸 、 双氧水 作用下， 生成 6-硝基烟酸
  参考文献：
  名称：

  Otsuji et al., Nippon Kagaku Zasshi, 1959, vol. 80, p. 1293,1295

  摘要：

  DOI：

文献信息

• Investigation of Fluorine-18 Labelled Peptides for Binding to Cholecystokinin-2 Receptors with High Affinity
  作者：Naeem-Ul-Haq Khan、Alicia Corlett、Craig A. Hutton、Mohammad B. Haskali

  DOI：10.1007/s10989-021-10310-z

  日期：2022.1

  CCK-2R binding, ligand-binding assays were conducted using A431 cells overexpressing human CCK-2R. MG11 2 modified by 4-fluorobenzoate (FB-MG11 3) demonstrated the highest binding affinity (0.20 nM) followed by MG11 2 modified by 6-fluoronicotinate (FNic-MG11 4; 0.74 nM) and 2-fluoropropionate (FP-MG11 5; 1.80 nM), respectively. Whilst indirect labelling of MG11 2 using fluorine-18 labelled activated

  摘要许多神经内分泌来源的癌症过度表达胆囊收缩素-2 受体 (CCK-2R)，包括甲状腺髓样癌、小细胞肺癌和其他肺癌类癌。靶向 CCK-2R 的 Fluorine-18 标记肽能够使用正电子发射断层扫描成像在体内直接可视化和量化该受体。CP04 1 和 MG11 2 是先前描述的两种截短肽，它们来源于天然 CCK-2R 激素配体胃泌素。MG11 2 八肽的N-末端用各种含氟芳族（4-氟苯甲酸酯）、杂环（6-氟烟酸酯）和脂肪族（2-氟丙酸酯）部分进行了化学修饰。为了评估这些修饰对 CCK-2R 结合的影响，使用过表达人 CCK-2R 的 A431 细胞进行配体结合测定。由 4-氟苯甲酸酯 (FB-MG11 3) 修饰的 MG11 2 表现出最高的结合亲和力 (0.20 nM)，其次是由 6-氟烟酸酯 (FNic-MG11 4; 0.74 nM) 和 2-氟丙酸酯 (FP-MG11 5; 1.80纳米），分别。虽然使用
• Synthesis of Spiro-dihydroquinoline and Octahydrophenanthrene Derivatives via Palladium-Catalyzed Intramolecular Oxidative Arylation
  作者：Zhong-Lin Zang、Shuklachary Karnakanti、Sheng Zhao、Ping Hu、Zhen Wang、Pan-Lin Shao、Yun He

  DOI：10.1021/acs.orglett.7b00228

  日期：2017.3.17

  A method for intramolecular sp2 C–H oxidative arylation of unactivated cyclic olefins has been developed to access spiro-dihydroquinoline and octahydrophenanthrene derivatives in a straightforward and efficient manner. Bearing picolinamide as a directing group, the alkenyl anilines cyclized to afford spiro-dihydroquinolines in moderate to excellent yields via direct oxidative arylation, while the alkenyl

  已开发出一种用于未活化环烯烃的分子内sp 2 C–H氧化芳基化的方法，以一种直接有效的方式获得螺二氢喹啉和八氢菲衍生物。链烯基苯胺以吡啶啉酰胺为导向基团，环化后可通过直接氧化芳基化反应以中等至优异的收率得到螺-二氢喹啉，而链烯基苄胺则通过顺序氧化芳基化和双乙酰氧基化反应以中等收率提供了八氢菲衍生物。
• Synthesis and Biological Evaluation of a Novel 18F-Labeled Radiotracer for PET Imaging of the Adenosine A2A Receptor
  作者：Thu Hang Lai、Magali Toussaint、Rodrigo Teodoro、Sladjana Dukić-Stefanović、Mathias Kranz、Winnie Deuther-Conrad、Rareş-Petru Moldovan、Peter Brust

  DOI：10.3390/ijms22031182

  日期：——

  The adenosine A2A receptor (A2AR) has emerged as a potential non-dopaminergic target for the treatment of Parkinson's disease and, thus, the non-invasive imaging with positron emission tomography (PET) is of utmost importance to monitor the receptor expression and occupancy during an A2AR-tailored therapy. Aiming at the development of a PET radiotracer, we herein report the design of a series of novel

  腺苷A2A受体（A2AR）已成为治疗帕金森氏病的潜在非多巴胺能靶标，因此，使用正电子发射断层扫描（PET）进行的非侵入性成像对监测受体的表达及其在患者中的占有率至关重要A2AR量身定制的疗法。针对PET示踪剂的发展，我们在此报告了基于A2AR拮抗剂zadendenant的结构和[18F] TOZ1的临床前评估的一系列新型氟化类似物（TOZ1-TOZ7）的设计。放射自显影证实了[18F] TOZ1与小鼠和猪脑纹状体的A2AR特异性体外结合。对小鼠代谢稳定性的研究表明，母体部分分别占血浆和脑样品总活性的76％和92％以上。
• Discovery of quinolone derivatives as antimycobacterial agents
  作者：Kun-Lin Liu、Fei Teng、Lu Xiong、Xiao Li、Chao Gao、Luo-Ting Yu

  DOI：10.1039/d0ra09250a

  日期：——

  6b21: MIC against M. tb H₃₇Rv = 1.2 μg mL⁻¹, MIC against drug-resistant strains = 0.9 μg mL⁻¹, solubility = 132 μg mL⁻¹, non-cytotoxicity.

  6b21：对H37Rv结核分枝杆菌的最小抑菌浓度为1.2 μg/mL，对耐药菌株的最小抑菌浓度为0.9 μg/mL，溶解度为132 μg/mL，无细胞毒性。
• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。